Invented by Paul Parren, Janine Schuurman, Tom Vink, Willem Karel Bleeker, Jan van de Winkel, Patrick van Berkel, Frank Beurskens, Genmab AS
The market for recombinant monovalent antibodies and methods for their production has been rapidly growing in recent years. These antibodies, also known as single-domain antibodies or nanobodies, are small antibody fragments derived from heavy-chain-only antibodies found in camelids and sharks. They have unique properties that make them highly attractive for various applications in research, diagnostics, and therapeutics.
One of the key advantages of recombinant monovalent antibodies is their small size, which allows them to access and bind to targets that are typically inaccessible to conventional antibodies. This makes them ideal for targeting intracellular proteins, membrane proteins, and other challenging antigens. Additionally, their small size enables better tissue penetration and distribution, leading to improved therapeutic efficacy.
The market for recombinant monovalent antibodies is driven by the increasing demand for more specific and effective therapeutics. These antibodies have shown great potential in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Their ability to target specific antigens with high affinity and selectivity makes them promising candidates for precision medicine approaches.
In terms of production methods, there are several approaches available for generating recombinant monovalent antibodies. One commonly used method is phage display, where a library of antibody fragments is displayed on the surface of bacteriophages. By selecting phages that bind to a specific target, researchers can isolate and amplify the DNA sequences encoding the desired antibodies.
Another method involves immunization of animals, such as llamas or sharks, with the target antigen. The immune response triggers the production of heavy-chain-only antibodies, which can then be isolated and engineered into monovalent antibody fragments. This approach has the advantage of generating antibodies with high affinity and specificity for the target antigen.
Furthermore, advancements in recombinant DNA technology have facilitated the production of recombinant monovalent antibodies in microbial expression systems. This allows for large-scale production, cost-effectiveness, and ease of purification. Various expression platforms, such as Escherichia coli and yeast, have been optimized for the production of these antibodies.
The market for recombinant monovalent antibodies is highly competitive, with several companies and academic institutions actively involved in research and development. Many pharmaceutical companies have recognized the potential of these antibodies and have entered into partnerships or collaborations to advance their development. Additionally, several start-ups have emerged, focusing specifically on the production and commercialization of recombinant monovalent antibodies.
In conclusion, the market for recombinant monovalent antibodies and the methods for their production are rapidly expanding. These antibodies offer unique advantages in terms of specificity, efficacy, and tissue penetration, making them highly valuable for various applications in research, diagnostics, and therapeutics. With ongoing advancements in technology and increasing investment in this field, the future looks promising for the market of recombinant monovalent antibodies.
The Genmab AS invention works as follows
The present invention provides monovalent antibody with a long in-vivo half-life, methods for making such monovalent antigens, pharmaceutical compositions containing such antibodies and uses of monovalent antigens.
Background for Recombinant Monovalent Antibodies and Methods for Production thereof
DESCRIPTION of FIGURES
Oligonucleotide Primer and PCR Amplification”.
Agarose Gel Electrophoresis
Analysis of PCR Products, Enzymatic Digestion Products and their Purification
Quantification DNA by UV Spectroscopy”.
Restriction enzyme Digestions
Ligation Of DNA Fragments
Screening Bacterial Colonies By PCR
Site-Directed MutagenesisClick here
to view the patent on Google Patents.